Omnix Medical Announces Excellent Topline Data from the Phase I Clinical Trial of its Novel Anti-Infective OMN6

– OMN6 demonstrates safety and tolerability at clinically significant dose levels  

Omnix Medical, a biopharmaceutical company developing next-generation anti-infectives for the treatment of life-threatening infections, today announced positive top-line results from the Phase I clinical trial of its lead compound OMN6, an anti-infective with a completely novel mechanism of action. All endpoints were met: No severe or serious adverse events (SEs/SAEs) were observed at any dose level in the study while clinically meaningful levels of OMN6 were achieved in the blood and complete clearance of the drug was demonstrated, allowing for multiple daily infusions as is common with anti-infective treatments.

Read more…

ImmunOs Therapeutics Appoints Michael A. Curran, PhD, as Chairman of its Scientific Advisory Board

– Renowned immunology expert from MD Anderson Cancer Center to lead seasoned group of scientific advisors

ImmunOs Therapeutics AG, a biopharmaceutical company leveraging its HLA-based technology platform to develop first-in-class therapeutics for the treatment of cancer and autoimmune diseases, today announced that Michael A. Curran, PhD, has been appointed Chairman of the Company´s Scientific Advisory Board. In addition to Dr. Curran, Taha Merghoub, PhD, Ulf Petrausch, MD, and Paul Bowness, MD, PhD, currently serve as Scientific Advisors to ImmunOs.

Read more…

ProBioGen and ImmunOs Therapeutics Team Up to Deliver Innovative Therapy for Cancer Patients

ProBioGen and ImmunOs Therapeutics announce the extension of their partnership for further large-scale manufacturing of clinical material for IOS-1002, ImmunOs’ lead program for the treatment of cancer. ProBioGen previously developed the cell line and the manufacturing process and provided the initial clinical material for ImmunOs’ innovative biologic.

Read more…

EBViously Announces First Details of Its EBV-001 Vaccine Candidate for the Prevention of Epstein-Barr Virus (EBV)-Induced Diseases

— Presentation at the World Vaccine Congress 2023

— EBV-infections associated with many cancers and multiple sclerosis

EBViously, a start-up developing novel vaccines based on next-generation virus-like particles, will present its approach and technology at the upcoming World Vaccine Congress 2023 (April 4-6, 2023) in Washington, DC (USA). The presentation will take place on Wednesday, April 5, 2023, at 2:55 p.m. EST in Room 201 of the Walter E. Washington Convention Center in Washington, DC.

Read more…

1 2 3 179